Rhino Biotech Limited
Other OTCTotal Valuation
Rhino Biotech Limited carries a market capitalization of 3,105.00, placing it among publicly traded companies globally. Its enterprise value stands at 2.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3,105.00 |
| Enterprise Value | 2.12M |
Share Statistics
Rhino Biotech Limited currently has 24.32M shares outstanding.
| Shares Outstanding | 24.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.49 |
| P/TBV Ratio | 4.28 |
| P/FCF Ratio | -2.83 |
| P/OCF Ratio | -2.83 |
Financial Position
Rhino Biotech Limited maintains a current ratio of 29.52, meaning it holds 29.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 29.52 |
| Quick Ratio | 28.06 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -222.67 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
EBITDA reached -799,386.00, while operating income came in at -814,694.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -814,694.00 |
| Pretax Income | N/A |
| Net Income | -1.37M |
| EBITDA | -799,386.00 |
| EBIT | -814,694.00 |
| Earnings Per Share (EPS) | -0.07 |
Balance Sheet
Total book value stands at -5.47M, with working capital of 576,758.00 providing operational flexibility.
| Cash & Cash Equivalents | 566,695.00 |
| Total Debt | N/A |
| Net Debt | -566,695.00 |
| Equity (Book Value) | -5.47M |
| Book Value Per Share | -0.26 |
| Working Capital | 576,758.00 |
Cash Flow
Rhino Biotech Limited produced -948,617.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -948,617.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -948,617.00 |
| FCF Per Share | -0.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -37.20 |
| FCF Yield | -35.29 |
Stock Splits
Rhino Biotech Limited's most recent stock split took place on July 15, 2005 with a 1:2 split ratio.
| Last Split Date | 7/15/2005 |
| Split Ratio | 1:2 |
Scores
Rhino Biotech Limited posts an Altman Z-Score of 64.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 64.81 |